Clinical trials: Survival , Tumor
Triple Negative Breast Neoplasms
A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC
This is a multicenter, open-label, randomized phase II trial evaluating the efficacy and safety of sacituzumab govitecan plus toripalimab versus toripalimab plus nab-paclitaxel in patients with previously untreated, unresectable…
- Trial name
- NCT07040644
- Testing
- Sacituzumab Govitecan (SG), Toripalimab, Nab-paclitaxel
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Gastric Cancer
A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer
This study will evaluate the disease free survival rate of a combination of capecitabine [Xeloda] and oxaliplatin (XELOX) with trastuzumab [Herceptin] in patients with resectable gastric cancer.
- Trial name
- NCT01130337
- Testing
- Capecitabine [Xeloda], Oxaliplatin, Trastuzumab [Herceptin]
- Where
- 30 sites in Spain
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Tumor Deposits, Colorectal Cancer
Tumor Deposits in Colorectal Cancer and Its Prognostic Value in Survival and Metastasis
This study aims to evaluate the tumor deposits in colorectal cancer and its prognostic value in survival and metastasis
- Conditions
- Tumor Deposits, Colorectal Cancer, Prognosis, Survival
- Trial name
- NCT06884839
- Testing
- Therapeutic resection
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Minia University
Ovarian Cancer, Endometrial Cancer
Improved Early Diagnosis in Female Pelvic Cancer With OC Detect
The goal of this observational study is to learn if so called Volatile Organic Compounds (VOCs) in blood can be used for early diagnosis of ovarian cancer.
- Conditions
- Ovarian Cancer, Endometrial Cancer, Breast Cancer, Lymphoma
- Trial name
- NCT06613230
- Where
- 2 sites in Sweden
- Volunteers
- 490 people
- Sponsor
- Region Skane
Hepatocellular Carcinoma
A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common malignances seen in different regions of the world. The 5-year risk of recurrence of HCC after resection has been reported to be as high as 70%.
- Trial name
- NCT02253511
- Testing
- Cidan capsule
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Zheng Donghai
Metastatic Colorectal Cancer
Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer
The purpose of this study is to evaluate the benefit of panitumumab in addition to best supportive care compared to best supportive care alone in patients with chemorefractory wild-type KRAS (Kirsten rat sarcoma viral oncogene…
- Trial name
- NCT01412957
- Testing
- Best Supportive Care (BSC), Panitumumab
- Where
- 78 sites in Brazil, Canada and 14 more
- Volunteers
- 377 people
- Sponsor
- Amgen
Multiple Myeloma
"WB-DCE-MRI" in Multiple Myeloma as an Independent Prognostic Factor for Disease-free Survival
The main objective of this study is to examine if absence of a satisfactory response on DCE-WB-MRI (see MR criteria of responders section) after completion of HDT followed by autologous stem-cell transplantation (ASCT) is an…
- Trial name
- EVALICEMM (NCT01171430)
- Testing
- Whole Body Dynamic Contrast Enhanced MRI (WB-DCE-MRI)
- Where
- France
- Volunteers
- 104 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Rectal Neoplasms
Predictive Factors of Disease-free Survival After Complete Pathological Response to Neoadjuvant Radiotherapy in Rectal Adenocarcinoma
Many data suggest that patients with low rectal adenocarcinoma who achieved ypT0N0 status have improved survival and disease-free survival (DFS) compared to all other stages however only few data are available regarding the…
- Trial name
- NCT03601689
- Testing
- rectal resection
- Where
- 8 sites in Algeria, Morocco
- Volunteers
- 84 people
- Sponsor
- Moroccan Society of Surgery
Ovarian Cancer, Breast Cancer
Comprehensive Outcomes for After Cancer Health
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer.
- Conditions
- Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer
- Trial name
- COACH (NCT05349227)
- Testing
- Digital Health Coaching Program, Fitbit
- Where
- 7 sites in United States
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- Pack Health
Metastatic Cancer
Prospective Validation of a Points Score System Predicting 30-day Survival
This is a one-stage single-arm phase II clinical trial designed to prospectively test the survival prediction tool as developed by Lee et al on patients referred to radiation oncology for palliative treatments.
- Trial name
- NCT05100342
- Testing
- Point score prediction tool for 30-day survival
- Where
- 3 sites in United States
- Volunteers
- 214 people
- Sponsor
- Indiana University
Ovarian Cancer
Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)
Epithelial ovarian carcinoma (EOC) is the 5th leading cause of death among women. Long-term survival is poor for the majority of women with EOC because many present with advanced disease.
- Trial name
- NCT00239980
- Testing
- dalteparin
- Where
- 9 sites in Canada
- Volunteers
- 77 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Rectal Adenocarcinoma
GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis
A prospective, open, multicenter, randomized III trial with two arms: Arm A: Primary tumor resection , followed by chemotherapy Arm B: Chemotherapy alone.
- Trial name
- GRECCAR8 (NCT02314182)
- Testing
- Primary tumor resection + chemotherapy, Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab
- Where
- 3 sites in France
- Volunteers
- 5 people
- Sponsor
- Hospices Civils de Lyon
Breast Cancer Female, Breast Neoplasm
HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life
The purpose of this study is to invite all people diagnosed with cancer who meet the eligibility criteria to complete questionnaires before their treatment begins and at regular intervals over time to assess the impact of cancer…
- Conditions
- Breast Cancer Female, Breast Neoplasm, Non-Hodgkin's B-cell Lymphoma, Non-Hodgkin's Lymphoma, Adult High Grade
- Trial name
- NCT03000192
- Where
- 111 sites in United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Ovarian Cancer
Frailty, Quality Of Life and Early Reversal of Temporary Defunctioning Stoma in Ovarian Cancer
Complete macroscopic surgical resection (CMR) requires extensive surgery and combined with chemotherapy confers best chance of survival in advanced ovarian cancer.
- Trial name
- FOLERO (NCT06298877)
- Testing
- Frailty and Quality of Life evaluation
- Where
- 4 sites in Sweden
- Volunteers
- 475 people
- Sponsor
- Sahar Salehi
Gastric Cancer
Continuous Infusion of FU Combined With Epirubicin and Oxaliplatin in Patients With A/MGC
The purpose of this study is to evaluate the efficacy and tolerability of the combination of epirubicin, oxaliplatin and 5-day continuous infusional 5-fluorouracil (EOF5 regimen) in patients with unresectable advanced or…
- Trial name
- NCT00767377
- Testing
- EOF5
- Where
- China
- Volunteers
- 163 people
- Sponsor
- Fudan University
Sedentary Lifestyle, Breast Neoplasms
Step by Step: A Tailored Walking Intervention for Breast Cancer Survivors
This study aims to recruit post-treatment breast cancer survivors for a 12-week 2-arm randomized walking intervention. All intervention materials will be delivered electronically.
- Conditions
- Sedentary Lifestyle, Breast Neoplasms, Survival Rate (Survivorship)
- Trial name
- NCT01845519
- Testing
- Tailored Email, Targeted Email
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Leanne Kaye
Treatment for Metastatic or Locally Advanced Cervical Cancer
Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer
This is a single arm open label phase II trial to evaluate the oral daily use of BKM 120 in patients with recurrent unresectable or metastatic cervical cancer after palliative cisplatin based regimen failure.
- Trial name
- NCT01613677
- Testing
- BKM120
- Where
- Brazil
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
The primary objective of this study is to improve the 2-year progression-free survival in children with high-risk solid tumors who are administered a maintenance regimen with continuous sirolimus administered on a backbone of…
- Trial name
- AflacST1903 (NCT04469530)
- Testing
- Sirolimus, Cyclophosphamide, Etoposide
- Where
- 5 sites in United States
- Volunteers
- 55 people
- Sponsor
- Emory University
Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
This clinical trial aims to evaluate the effectiveness of tirzepatide in achieving a 5% or more body weight reduction in patients undergoing adjuvant treatment for hormone receptor-positive, HER2-negative (HR+/Her2-) breast…
- Trial name
- FITWISE (NCT06518837)
- Testing
- Tirzepatide
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rutgers, The State University of New Jersey
Acute Myeloid Leukemia, MDS
ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS
ClAraC (consisting of one dose of clofarabine and ara-C for five days) or FLAMSA (consisting of one dose of fudarabine, amsacrine and ara-C for four days) will be administered followed by reduced-intensity conditioning regimen…
- Trial name
- ClAraC-SCT (NCT01423175)
- Testing
- Clofarabine, ara-C, FLAMSA
- Where
- 3 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Hannover Medical School
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.